Loading clinical trials...
Loading clinical trials...
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
The study is a real-world study and the case records of patients with COVID-19 who visit Huashan Hospital affiliated to Fudan University from 2022 to 2027 and receive Paxlovid therapy will be collected in this study. The medical data including patient demographic, clinical characteristics, laboratory examination, history of treatments, adverse reactions and treatment outcome will be extracted to analyze the effectivity and safety of paxlovid and explore the prognosis-relevant factors of COVID-19.
Age
12 - No limit years
Sex
ALL
Healthy Volunteers
No
Huashan Hospital Affiliated to Fudan University
Shanghai, China
Start Date
March 21, 2022
Primary Completion Date
March 30, 2023
Completion Date
March 30, 2027
Last Updated
May 24, 2022
2,000
ESTIMATED participants
Paxlovid
DRUG
Lead Sponsor
Huashan Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06631287